Check 35,000+ stocks against 26 valuation models and 37 quality factors

Taysha Gene Therapies Inc (TSHA) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Taysha Gene Therapies Inc $0.70, price $4.63, upside -84.9%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US · ISIN US8776191061

Thin data Sep 28, 2026

Taysha Gene Therapies Inc

TSHA · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.7000 · Strongly overvalued (−84.9%)

!Quality 25/100

!Mixed Growth (revenue 3y +57.5 %/yr)

!Low debt · negative free cash flow

!Trails peers (1/7)

!Narrow moat 9/100

!Insider activity 46/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.4600 to bull $0.8800 Growth analysisrevenue history, year by year Quality 25/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Taysha Gene Therapies Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.

How to read this chart

60‑month range $0.5900 – $21.57 · fair‑value band $0.4600 – $0.8800 · the $4.63 price screens above the $0.7000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.

Follow Taysha Gene Therapies in your weekly email

Every Wednesday you see whether Taysha Gene Therapies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Stock analysis

Taysha Gene Therapies Inc (TSHA) currently trades at $4.63, while our model-based Fair Value estimate is $0.7000, 84.9% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.4600 (bear) to $0.8800 (bull), the price of $4.63 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Taysha Gene Therapies Inc reported revenue of $9.8M in FY2025 versus $0 in FY2021. Reported net income was −$109M in FY2025.

Key figures

Market cap $1.7B · EPS (TTM) $−0.4100 · Return on equity −47.1% · Return on assets (EBIT) −62.4% · Operating margin −2,792% · Revenue (TTM) $5.5M · Revenue growth (YoY) +171% · Free cash flow −$93.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 34% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, TSHA screens richer than that median.

Fair Value models

Bear $0.4600 Fair Value $0.7000 Bull $0.8800

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $0.3800 $0.5100 $0.7600 54

All 1 models by family

Asset-Based

NCAV (Graham) $0.3800 $0.5100 $0.7600 54

Open the full fair value analysis →

Notify me when TSHA reaches fair value

Put TSHA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 32 · Market factors (momentum, volatility) 45

Profitability 1

Margins and returns on capital today

Quality Growth 53

Are margins and returns improving?

Cashflow 8

Earnings quality: real cash, not paper profit

Fin. Strength 98

Balance sheet, leverage, solvency risk

Investment 23

Disciplined investing over empire-building

Low Volatility 24

Calm price path (market factor)

Momentum 54

Price trend over the last 3–12 months (market factor)

52W Momentum 55

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+17.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+57.5%

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−5,037.1% (2022) → −1,130.6% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

TSHA screens overvalued: fair value 85% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Taysha Gene Therapies Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 629 stocks

Beats the industry median on 1/6 measures

Overall it trails its industry peers.

Valuation

Quality Score 32 · Bottom 25%

Fair Value upside −85.2% · Bottom 25%

Profitability

Return on assets −23.8% · Below median

Growth and dividend

Revenue growth 171.3% · Top 25%

Balance sheet

Debt / equity 0.20× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.08× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)100 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)90 · sector 97

DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$527.67	$580.44	+10%
Regeneron Pharmaceuticals, Inc REGN	$752.25	$1,275	+69%
argenx SE ARGX	$959.49	$918.60	−4%
CSL Limited CSL	A$175.35	A$192.89	+10%
Samsung Biologics Co 207940	1,354,000 KRW	1,489,400 KRW	+10%
BeOne Medicines AG ONC	$360.85	$280.94	−22%
Alnylam Pharmaceuticals, Inc ALNY	$255.96	$217.88	−15%
Royalty Pharma plc RPRX	$58.21	$19.01	−67%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
WuXi Biologics (Cayman) Inc 2269	HK$53.00	HK$58.30	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Taysha Gene Therapies Inc · Fair Value
$0.7000 −85%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/TSHA" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Taysha Gene Therapies Inc · Fair Value</span><br><b style="font-size:20px">$0.7000</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−85%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Taysha Gene Therapies Inc Fair Value". https://www.fairvalue-calculator.com/stock/TSHA

Frequently asked questions

Is Taysha Gene Therapies Inc (TSHA) overvalued or undervalued?

As of Sep 28, 2026, our model estimates a fair value of $0.7000 versus a price of $4.63, about −85% upside (overvalued).

What is the fair value of TSHA?

Our model-based fair value for Taysha Gene Therapies Inc is $0.7000 (as of Sep 28, 2026), built from audited fundamentals. The current price: $4.63.

What is the quality score of TSHA?

Taysha Gene Therapies Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Taysha Gene Therapies Inc (TSHA)?

Our model-based price target is the fair value of $0.7000 (as of Sep 28, 2026) from 1 valuation models. Cautious scenario $0.4600, optimistic scenario $0.8800. It is a calculation from audited fundamentals, not an analyst target.

What is the Taysha Gene Therapies Inc stock forecast for 2026?

Our models put fair value at $0.7000, about −85% upside versus a price of $4.63 (overvalued). Cautious scenario $0.4600, optimistic scenario $0.8800. The calculation is refreshed regularly with new filings.

What is the revenue of Taysha Gene Therapies Inc (TSHA)?

Taysha Gene Therapies Inc reported trailing-twelve-month revenue of about $5.5M (latest available figure, as of Sep 28, 2026).

What is the intrinsic value of Taysha Gene Therapies Inc (TSHA)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Taysha Gene Therapies Inc it is $0.7000 per share (as of Sep 28, 2026), against a price of $4.63. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Taysha Gene Therapies Inc stock overvalued or undervalued in 2026?

As of Sep 28, 2026, TSHA trades above its calculated fair value: price $4.63, fair value $0.7000, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of TSHA?

No. The price is what the market pays today ($4.63); the fair value is what the company's own numbers justify ($0.7000). For Taysha Gene Therapies Inc the two are $3.93 per share apart. That gap is exactly why we show both numbers side by side.

How much is Taysha Gene Therapies Inc worth?

The market values Taysha Gene Therapies Inc at about $1.7B (market capitalisation, as of Sep 28, 2026). Per share that is $4.63; our models calculate a fair value of $0.7000 per share.

What do the bullish and bearish scenarios say about TSHA?

Our models span a range for Taysha Gene Therapies Inc: cautious scenario $0.4600, base $0.7000, optimistic $0.8800 per share (as of Sep 28, 2026, price $4.63). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Taysha Gene Therapies Inc (TSHA)?

Balance-sheet figures for Taysha Gene Therapies Inc (as of Sep 28, 2026): return on equity −47.1%, debt of 0.20 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.

How far is TSHA from its 52-week high?

Taysha Gene Therapies Inc trades at $4.63, about 34% below its 52-week high of $6.98 and 21% above the low of $3.83 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7000 is for.

Which stocks are comparable to Taysha Gene Therapies Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Taysha Gene Therapies Inc stock attractive at the current price?

The data as of Sep 28, 2026: price $4.63, calculated fair value $0.7000 (−85%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of TSHA calculated?

We run Taysha Gene Therapies Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.7000, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Taysha Gene Therapies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Taysha Gene Therapies Inc (TSHA)?

The closing price on Oct 2, 2026 was $4.63. Our model-based fair value is $0.7000, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Taysha Gene Therapies Inc right now?

The price sits above even our optimistic bull case ($0.8800). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4600 to $0.8800) leaves room in how you read the outcome.

Key figures of Taysha Gene Therapies Inc

How large is the market capitalisation of Taysha Gene Therapies Inc (TSHA)?

The market capitalisation of Taysha Gene Therapies Inc is $1.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Taysha Gene Therapies Inc (TSHA)?

Earnings per share at Taysha Gene Therapies Inc are $−0.4100. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Taysha Gene Therapies Inc (TSHA)?

The return on equity (ROE) of Taysha Gene Therapies Inc is −47.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Taysha Gene Therapies Inc (TSHA)?

On an EBIT basis the return on assets of Taysha Gene Therapies Inc is −62.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Taysha Gene Therapies Inc (TSHA)?

The operating margin of Taysha Gene Therapies Inc is −2,792% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Taysha Gene Therapies Inc (TSHA)?

Revenue at Taysha Gene Therapies Inc is growing +171% versus a year earlier (3y avg +57.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Taysha Gene Therapies Inc (TSHA) generate?

The free cash flow of Taysha Gene Therapies Inc is −$93.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Taysha Gene Therapies Inc (TSHA) hold?

Taysha Gene Therapies Inc holds more cash than debt, $302M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Taysha Gene Therapies Inc in the live analysis

One click puts Taysha Gene Therapies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.